Bispecific Antibodies Are Emerging As New Era Of Targeted Cancer Immunotherapies With More Than USD 40 Billion In Market Opportunities Says Kuick ResearchDelhi, Dec. 09, 2021 (GLOBE NEWSWIRE ...

A news feature on the research paper "Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition" by Rackear et al. was published in Oncotarget's Volume 15 on November 22 ...

Montréal-based biotech company KisoJi Biotechnology has raised $57 million CAD ($41 million USD) to bring its cancer treatment into clinical trials and leverage artificial intelligence (AI) for its ...

Nascent Biotech, Inc., a clinical-stage biotechnology Company developing monoclonal antibodies targeting various cancer types, and HypoSpray Pharma, a clinical and commercial stage drug delivery ...

Antibody-drug conjugates (ADCs) are at the forefront of cancer therapy, combining targeted precision with potent cytotoxicity. Conceived by Paul Ehrlich in the early 1900s, the concept of a magic ...